LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Advanced Sequencing Techniques Determine Cancer Genome Variants in Young Patients

By LabMedica International staff writers
Posted on 03 Aug 2021
Typical RNA sequencing workflow (Photo courtesy of Wikimedia Commons)
Typical RNA sequencing workflow (Photo courtesy of Wikimedia Commons)
A recent paper described a three-platform sequencing approach, including whole genome (WGS), exome, and RNA sequencing, that was used to examine tumor and germline genomes from prospectively identified children with newly diagnosed or relapsed/refractory cancers.

Investigators at St. Jude Children's Research Hospital (Memphis, TN, USA) analyzed samples obtained from participants in the "Genomes for Kids" study. Genomes for Kids, which has enrolled about 2,700 cancer patients, is St. Jude’s clinical genomics program. Data generated through the Genomes for Kids project has been made available at no cost to the international research community.

For the current study, whole genome, whole exome, and RNA sequencing of tumor DNA was carried out for 253 patients for whom adequate tumor samples were available.

Results revealed that 86% of patients harbored diagnostic (53%), prognostic (57%), therapeutically-relevant (25%), and/or cancer predisposing (18%) variants. Inclusion of WGS enabled detection of activating gene fusions and enhancer hijacks (36% and 8% of tumors, respectively), small intragenic deletions (15% of tumors), and mutational signatures revealing of pathogenic variant effects. Germline variations in one of 156 known, cancer-predisposition genes were identified in 18% of the patients.
Almost two-thirds of the germline variations identified would not have been detected based on current screening guidelines.

"This study showed the feasibility of identifying tumor vulnerabilities and learning to exploit them to improve patient care," said senior author Dr. David Wheeler, director of the precision genomics team at St. Jude Children's Research Hospital. "We want to change the thinking in the field. We showed the potential to use genomic data at the patient level. Even in common pediatric cancers, every tumor is unique, every patient is unique."

The Genomes for Kids study was published in the July 23, 2021, online edition of the journal Cancer Discovery.

Related Links:

St. Jude Children's Research Hospital

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more